<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04581733</url>
  </required_header>
  <id_info>
    <org_study_id>MT-1621-104</org_study_id>
    <nct_id>NCT04581733</nct_id>
  </id_info>
  <brief_title>A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)</brief_title>
  <official_title>A Phase 3b Single Arm Clinical Study to Evaluate the Efficacy and Safety of MT1621 in Nucleos(t)Ide Treatment Naïve Pediatric and Adolescent Subjects With Thymidine Kinase 2 (TK2) Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Modis Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zogenix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Modis Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3b, prospective, single-arm, multicenter, open-label treatment study of the&#xD;
      efficacy and safety of MT1621 in pediatric and adolescent patients with thymidine kinase 2&#xD;
      deficiency (TK2d). In order to be eligible for this study, participants must have genetic&#xD;
      confirmation of TK2d and must not have ever received MT1621 or nucleos(t)ides before entering&#xD;
      the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thymidine kinase 2 (TK2) is a protein involved in the normal function of mitochondria.&#xD;
      Thymidine kinase 2 deficiency (TK2d) is a form of mitochondrial DNA depletion syndrome and is&#xD;
      a very rare inherited genetic disorder. TK2d leads to abnormally low amounts of DNA in&#xD;
      mitochondria and because of this defect, the mitochondria are not able to provide the energy&#xD;
      that cells need to function properly, which causes severe muscle weakness, along with host of&#xD;
      additional symptoms that may involve the respiration, feeding, and ambulation, and can&#xD;
      progress until patients lose many of these abilities. There are no FDA-approved medicines to&#xD;
      treat TK2d.&#xD;
&#xD;
      MT1621 is a therapy that targets the underlying pathophysiology of TK2d by restoring&#xD;
      mitochondrial DNA (mtDNA) replication fidelity. MT1621 consists of a combination of&#xD;
      deoxynucleosides (the building blocks of mtDNA) given orally. Deoxynucleoside combination&#xD;
      therapy improves nucleotide balance, increases mtDNA copy number, improves cell function, and&#xD;
      prolongs life in preclinical models of TK2d.&#xD;
&#xD;
      This is a Phase 3b, prospective, single-arm, multicenter, open-label treatment study to&#xD;
      assess the efficacy and safety of MT1621 in treatment naïve pediatric and adolescent subjects&#xD;
      &lt;18 years of age with TK2d. The study seeks to enroll approximately 16 subjects globally in&#xD;
      this ultra rare disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a Phase 3b study. All participants will receive MT1621 up to a target dose of 400 mg/kg/day</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects acquiring a Motor Milestone</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of subjects acquiring a motor milestone not present at baseline after 12 months of MT1621 treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Acquisition of a Motor Milestone</measure>
    <time_frame>12 months</time_frame>
    <description>Time to Acquisition of a Motor Milestone that was not present at baseline after 12 months of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>12 months</time_frame>
    <description>Survival after 12 months of treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Thymidine Kinase 2 Deficiency</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Male and female Participants &lt;18 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT1621</intervention_name>
    <description>All patients will receive MT1621 up to a target dose of 400 mg/kg/day each dC and dT, as tolerated.</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>Deoxycytidine (dC) and deoxythymidine (dT)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject must be aged birth to &lt;18 years of age on the day of consent.&#xD;
&#xD;
          -  Diagnosis of TK2 deficiency based on confirmed disease-causing mutation(s) in the TK2&#xD;
             gene.&#xD;
&#xD;
          -  Onset of TK2d at ≤12 years of age as defined as the age at which the first TK2d&#xD;
             symptom occurred.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Documented clinically significant central nervous system involvement.&#xD;
&#xD;
          -  ALT or AST &gt;3 x upper limit of normal and total bilirubin &gt; 2 x ULN or International&#xD;
             Normalized Ratio (INR) &gt;1.5.&#xD;
&#xD;
          -  EtCO2&gt;45 mmHg if not on ventilatory support&#xD;
&#xD;
          -  Current or prior treatment with nucleos(t)ides for TK2d.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan VanMeter, MD</last_name>
    <role>Study Director</role>
    <affiliation>Zogenix, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zogenix Clinical Trials Information Desk</last_name>
    <phone>510-920-9700</phone>
    <email>MT1621ClinStudyInfo@zogenix.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Diego Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Margo Hammack</last_name>
      <email>mhammack@health.ucsd.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 29, 2020</study_first_submitted>
  <study_first_submitted_qc>October 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2020</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TK2</keyword>
  <keyword>TK2d</keyword>
  <keyword>mitochondrial disorder</keyword>
  <keyword>mitochondrial disease</keyword>
  <keyword>Mitochondria</keyword>
  <keyword>deoxythymidine/deoxythymidine substrate enhancement therapy</keyword>
  <keyword>dC/dT</keyword>
  <keyword>deoxythymidine/deoxythymidine</keyword>
  <keyword>primary mitochondrial myopathy</keyword>
  <keyword>mitochondrial depletion syndrome</keyword>
  <keyword>Muscle weakness</keyword>
  <keyword>Muscle atrophy</keyword>
  <keyword>Loss of mobility</keyword>
  <keyword>Thymidine kinase 2 deficiency</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

